GSK plc (LON:GSK) Receives GBX 2,016.43 Average Price Target from Analysts

Shares of GSK plc (LON:GSK) have received an average rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is GBX 2,016.43.

A number of equities analysts recently weighed in on the stock. UBS Group reaffirmed a “neutral” rating and issued a GBX 1,940 target price on shares of GSK in a research note on Friday, January 23rd. Citigroup boosted their price target on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research report on Monday, February 9th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Finally, Berenberg Bank reaffirmed a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a report on Thursday, March 26th.

GSK Price Performance

Shares of LON GSK opened at GBX 2,176 on Wednesday. The firm has a market cap of £86.97 billion, a PE ratio of 15.68, a PEG ratio of 1.24 and a beta of 0.35. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 108.20. GSK has a 1-year low of GBX 1,263.50 and a 1-year high of GBX 2,282. The company has a fifty day moving average price of GBX 2,101.01 and a 200 day moving average price of GBX 1,875.16.

GSK (LON:GSK) last announced its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. Research analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Activity at GSK

In related news, insider Jonathan Symonds purchased 5,000 shares of the stock in a transaction on Friday, March 20th. The shares were purchased at an average cost of GBX 1,951 per share, with a total value of £97,550. Also, insider Anne Beal purchased 196 shares of the stock in a transaction on Friday, March 20th. The stock was bought at an average cost of GBX 5,179 per share, for a total transaction of £10,150.84. Insiders bought 11,447 shares of company stock valued at $24,273,097 in the last 90 days. Insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.